Our Platform
Unlocking the potential of protein stabilisation
Outrun combines our world class knowledge of E3 ligase biology and protein-to-protein interactions with our proprietary discovery platform to identify first-in-class small molecule drugs targeting E3 ligases.
Our platform – X-E3L
Outrun’s X-E3L (Crosslinking E3 Labeller) platform is scalable and modular, enabling the generation of E3 ligase inhibitors that stabilise proteins.
Despite the very high interest in E3 ligases as a therapeutic target, they have been challenging to drug in the past.
Our platform – X-E3L
Outrun’s X-E3L (Crosslinking E3 Labeller) platform is scalable and modular, enabling the generation of E3 ligase inhibitors that stabilise proteins.
Despite the very high interest in E3 ligases as a therapeutic target, they have been challenging to drug in the past.
Our elegant, engineered platform is enabling us to build a pipeline of highly valuable, small molecule, first-in-class, E3 ligase inhibitors to prevent protein degradation, as well as identify novel E3 ligase targets involved in a range of diseases.
Our world class knowledge of E3 ligase biology and our proprietary discovery platform simplifies and dramatically scales the assessment of E3 ligase targets, thereby significantly reducing discovery time.
Lead Programme
Our lead programme is a small molecule inhibitor targeting an E3 ligase that destabilises a tumour suppressor protein in hard-to-treat solid tumours.
© Outrun Therapeutics
